Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
519 hedge funds and large institutions have $21.8B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 160 increasing their positions, 209 reducing their positions, and 82 closing their positions.
3% less capital invested
Capital invested by funds: $22.5B → $21.8B (-$721M)
6% less funds holding
Funds holding: 553 → 519 (-34)
13% less funds holding in top 10
Funds holding in top 10: 83 → 72 (-11)
23% less repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 209
35% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 82
40% less call options, than puts
Call options by funds: $2.21B | Put options by funds: $3.69B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$699M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$158M |
| 3 |
D.E. Shaw & Co
New York
|
+$154M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$141M |
| 5 |
SCM
Segantii Capital Management
Hong Kong
|
+$114M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$331M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$181M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$175M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$173M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
-$129M |
HZNP Hedge Fund Activity: Q2 2023 in Review
519 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2023, worth a combined $21.8B — down 3.2% from $22.5B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of HZNP and 53 opened new positions — a net loss of 29 holders — while 209 trimmed existing stakes and 160 added.
The largest buyer was Pentwater Capital Management, adding an estimated $699M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $331M sold.
- 519 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2023, down from 553 in Q1 2023.
- Funds reported $21.8B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2023, down 3.2% quarter-over-quarter.
- 53 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2023 and 82 closed out, a net change of -29 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2023 was Pentwater Capital Management, an estimated $699M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2023 was T. Rowe Price Investment Management, an estimated $331M sold.
Based on aggregated 13F filings for Q2 2023.